BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5 | $7 | $1 | $2 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $2 | $2 | $2 | $2 |
| Enterprise Value | $6 | $8 | $2 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,285.3% | -88% | 11.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.3% | 73.7% | 95.6% | 95.5% |
| EBITDA | -$0 | -$1 | -$0 | -$1 |
| % Margin | -196.9% | -6,078.3% | -511.9% | -765.7% |
| Net Income | -$1 | -$1 | -$0 | -$1 |
| % Margin | -241.4% | -6,913.9% | -619.7% | -806.9% |
| EPS Diluted | -2.88 | -3.95 | -3.35 | -4.43 |
| % Growth | 27.1% | -17.9% | 24.4% | – |
| Operating Cash Flow | -$1 | -$1 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$1 | -$1 | -$0 | -$1 |